Recruiting

Observational Study

Sponsor:

Albert Einstein College of Medicine

Code:

NCT05854563

Conditions

Lung Diseases

Lung Cancer

Lung Diseases, Obstructive

Lung Diseases, Interstitial

Lung Inflammation

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Interventions

Observational only, all subjects; measure DNA mutation and proteomic survey.

Study Details

Brief summary:

The lung is a privileged organ; blood does not reflect most lung processes well, if at all. Therefore, for population scale diagnostics, the investigator team is developing non-invasive portals to the lung, for eventual early detection/risk assessment and diagnostic purposes. However, large macromolecules are not likely suspended nor readily detected in the breath. In particular, genomic DNA in the breath condensate (EBC) is very sparse, and where present, generally highly fragmented, not readily amenable to sequencing based assessments of DNA somatic mutation burden or distribution. Because gDNA (and protein) is challenging to obtain non-invasively from EBC, the study team considered alternative surrogate lower airway specimens. Cough capture is rarely done, and the investigator team is in the process of optimizing its collection. Importantly, the team will be evaluating how much of coughed material is from saliva contamination. Additionally, analyzing material that is target captured by capturing deep lung extracellular vesicles (EVs) using immobilized CCSP/SFTPC antibodies targeting EVs from distal bronchiole Club and alveolar type 2 cells could circumvent the mouth contamination problem, leaving a non-invasive portal to the deep lung suitable for large molecules, and in turn suitable for myriad epidemiologic and clinical applications.

The investigator team proposes (Aim 1) to pursue optimizing cough collection, and testing the efficacy and practicality of partitioning cough specimen for deep-lung specific extra-cellular vesicles (EVs). This cough specimen will be compared to that from invasively collected deep lung samples BAL/bronchial brushings, and to the potential contaminating mouth rinse, all from the same individuals. (Aim 2) The study team initially proposes to examine these cough specimens for somatic mutations by SMM bulk sequencing for single nucleotide variation, developed in the Vijg/Maslov labs. Finally, the investigator team will (Aim 3) test all airway specimens (cough, mouthwash and BAL) for lung surrogacy of cough, using proteins known to be specific for lung, as opposed to oral cavity/saliva, in the Sidoli/proteomics core.

The investigator team envisions that the translational impact of non-invasively obtained DNA or protein markers could allow for more rapid acute clinical diagnoses, and facilitate precision prevention and/or early detection of many acute and chronic respiratory disorders, including lung cancer, asthma and COPD, acute and chronic infectious diseases, and indeed systemic disorders of inflammation and metabolism.

Conditions

Lung Diseases

Lung Cancer

Lung Diseases, Obstructive

Lung Diseases, Interstitial

Lung Inflammation

Study ID

NCT05854563

Start date

Mar 28, 2023

Status verified date

Jan, 2026

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age: minimum age of 21 years
  • Gender: Male and Female adults
  • Ethnicity: All ethnic groups and races
  • Subjects undergoing bronchoscopy for diagnostic purposes or therapy
  • Subjects without a known diagnosis of lung cancer who are not scheduled for lung tissue collection procedures
  • Subjects with a known or suspected diagnosis of asthma or COPD and are scheduled for a visit at Montefiore Asthma or COPD Center and individual practices, and/or in-hospital with exacerbation

Exclusion Criteria:

  • Bleeding diathesis or known coagulopathy precluding clinically indicated biopsy (e.g., INR>1.3, PTTr>1.3), thrombocytopenia <50,000, uremia with serum creatinine >3.0
  • Unstable angina
  • Recent myocardial infarction (within 3 months),
  • Uncontrolled congestive heart failure or severe pulmonary hypertension (mean PAP>75 mmHg)

Study Design

Enrollment

2000 participants

Anticipated

Interventions and Outcome Measures

Arms

Bronchoscopy subjects, current or former smokers

Bronchoscopy subjects >=21 yo, current or former smokers

Bronchoscopy subjects, never smokers

Bronchoscopy subjects >=21 yo, never smokers

Interventions

Observational only, all subjects; measure DNA mutation and proteomic survey.

Observational only, all subjects; measure DNA mutation and proteomic survey.

Primary outcome measure

  • Number of smoker and non-smoker participants demonstrating somatic DNA mutations as evidenced by mutation burden [ Time Frame: Up to 30 minutes for collection of all airway samples ]
  • Aggregate Median Mutation Rate in smoker and non-smoker participants [ Time Frame: Up to 30 minutes for collection of all airway samples ]
  • Number of smoker and non-smoker participants demonstrating altered protein expression [ Time Frame: Up to 30 minutes for collection of all airway samples ]
  • Proteomic signature comparison in smoker and non-smoker participants [ Time Frame: Up to 30 minutes for collection of all airway samples ]

Central Contacts and Locations

Locations

Albert Einstein College of Medicine

Recruiting

The Bronx, New York, United States, 10461

Contacts

More Information

Sponsor

Albert Einstein College of Medicine

Last update posted

Jan 13, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Albert Einstein College of Medicine on 2026-01-13.